Maria Esperanza Rodriguez-Ruiz

List of Publications by Year
in descending order

83 papers	6,541 citations	136740 32 h-index	133063 59 g-index
84 all docs	84 docs citations	84 times ranked	11081 citing authors

#	Article	IF	Citations
1	Cytokines in clinical cancer immunotherapy. British Journal of Cancer, 2019, 120, 6-15.	2.9	720
2	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine, 2019, 25, 470-476.	15.2	459
3	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	6.6	387
4	Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Antiâ€“PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discovery, 2016, 6, 71-79.	7.7	356
5	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	0.6	326
6	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	13.7	313
7	Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends in Immunology, 2018, 39, 644-655.	2.9	312
8	Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews, 2017, 60, 24-31.	3.4	262
9	Emerging Opportunities and Challenges in Cancer Immunotherapy. Clinical Cancer Research, 2016, 22, 1845-1855.	3.2	242
10	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nature Immunology, 2020, 21, 120-134.	7.0	218
11	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research, 2014, 20, 5697-5707.	3.2	200
12	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	7.7	197
13	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research, 2016, 76, 5994-6005.	0.4	191
14	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655.	0.8	179
15	Intratumoral Delivery of Immunotherapyâ€”Act Locally, Think Globally. Journal of Immunology, 2017, 198, 31-39.	0.4	171
16	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â^'/â^'IL2Rî³null Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478.	0.4	137
17	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 3002-3002.	0.8	129
18	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	2.4	111

#	Article	IF	Citations
19	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology, 2018, 29, 1312-1319.	0.6	106
20	Deciphering CD137 (4â€1BB) signaling in Tâ€cell costimulation for translation into successful cancer immunotherapy. European Journal of Immunology, 2016, 46, 513-522.	1.6	104
21	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. OncoImmunology, 2019, 8, e1655964.	2.1	97
22	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
23	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
24	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
25	TGFÎ² Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. Molecular Cancer Therapeutics, 2019, 18, 621-631.	1.9	68
26	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
27	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€"Derived Vectors Fosters Dendritic Cellâ€"Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.4	60
28	Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. International Journal of Radiation Oncology Biology Physics, 2017, 97, 389-400.	0.4	55
29	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. OncoImmunology, 2016, 5, e1062967.	2.1	52
30	Immune mechanisms mediating abscopal effects in radioimmunotherapy. , 2019, 196, 195-203.		52
31	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic antiâ€"PD-1 for patients with antiâ€"PD-1â€"refractory tumors. Science Translational Medicine, 2020, 12, .	5.8	51
32	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp>â€8. Journal of Pathology, 2021, 255, 190-201.	2.1	49
33	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€"PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	0.5	48
34	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discovery, 2016, 6, 1312-1314.	7.7	41
35	A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. , 2018, 6, 96.		40
36	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology, 2016, 37, 13687-13694.	0.8	37

#	Article	IF	Citations
37	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	7.7	36
38	Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clinical Cancer Research, 2017, 23, 5326-5328.	3.2	33
39	Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).. Journal of Clinical Oncology, 2018, 36, e15155-e15155.	0.8	33
40	Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy, 2017, 16, 1246-1251.	0.2	32
41	Differential Interleukinâ€8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology, 2021, 51, 2274-2280.	1.6	32
42	Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer. Brachytherapy, 2014, 13, 219-224.	0.2	26
43	Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
44	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
45	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discovery, 2022, 12, 1356-1377.	7.7	22
46	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nature Communications, 2021, 12, 7296.	5.8	22
47	Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.. Radiation Oncology, 2012, 7, 50.	1.2	21
48	Apoptotic caspases cut down the immunogenicity of radiation. OncoImmunology, 2019, 8, e1655364.	2.1	19
49	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
50	Functional expression of CD137 (4-1BB) on T helper follicular cells. OncoImmunology, 2015, 4, e1054597.	2.1	15
51	Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?. Cancer Immunology, Immunotherapy, 2016, 65, 493-497.	2.0	15
52	Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. Journal of Translational Medicine, 2014, 12, 98.	1.8	13
53	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Clinical and Translational Oncology, 2019, 21, 992-1004.	1.2	13
54	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology, 2018, 29, viii732.	0.6	8

#	Article	IF	Citations
55	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
56	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4â€“1BB). OncoImmunology, 2018, 7, e1368605.	2.1	7
57	A proposal for the stratification of the risk of locoregional failure after surgical resection, perioperative high dose rate brachytherapy, and external beam irradiation: The University of Navarre predictive model. Brachytherapy, 2014, 13, 400-404.	0.2	6
58	Abstract 536: NBTXR3 potentiate cancer-cell intrinsic interferon beta response to radiotherapy. , 2019, , .		6
59	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Cancer Research, 2016, 76, 2863-2867.	0.4	4
60	Consolidating Radiotherapy with Immunotherapy. Clinical Cancer Research, 2021, 27, 5443-5445.	3.2	4
61	Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. OncoImmunology, 2020, 9, 1760676.	2.1	4
62	Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells. , 2016, , .		4
63	Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2RÎ³null immunodeficient mice. , 2015, , .		3
64	Study of kidney damage in pediatric patients with neurogenic bladder and its relationship with the pattern of bladder function and treatment received. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 37-42.	0.2	2
65	VISTA Blockade Immunotherapy in a MULTI-Modal Approach to Triple Negative Breast Cancer (TNBC) in MICE and IMPACT on Microbiome. International Journal of Radiation Oncology Biology Physics, 2019, 105, S88-S89.	0.4	2
66	Monitoring abscopal responses to radiation in mice. Methods in Enzymology, 2020, 635, 111-125.	0.4	2
67	Pneumomediastinum as a complication of SABR for lung metastases. Radiation Oncology, 2015, 10, 25.	1.2	1
68	Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. , 2018, , .		1
69	Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status.. Journal of Clinical Oncology, 2019, 37, 1540-1540.	0.8	1
70	Patterns of Failure in Patients With Glioblastoma Treated With Surgery and Intensity Modulated Radiation Therapy and Temozolomide. International Journal of Radiation Oncology Biology Physics, 2012, 84, S273.	0.4	0
71	Induction Chemotherapy (I-CHT) Followed by Intensity Modulated Radiation Therapy Using Simultaneously Integrated Boost (IMRT-SIB) and Concomitant Chemotherapy and Cetuximab (C-CHT) for Locally Advanced Squamous Head-and-Neck Carcinomas (SHNC).. International Journal of Radiation Oncology Biology Physics, 2012, 84, S527.	0.4	0
72	Phase Ii Study with Immunotherapy with Dendritic Cells (Dc) Combined with Intratumoral Hiltonol in Patients with Advanced Cancer. Annals of Oncology, 2014, 25, iv371.	0.6	0

#	Article	IF	Citations
73	Combined immunotherapy encompassing intratumoral polyICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology, 2017, 28, xi14.	0.6	0
74	Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens. Annals of Oncology, 2018, 29, viii435-viii436.	0.6	0
75	Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC). Annals of Oncology, 2018, 29, viii651-viii652.	0.6	0
76	International Symposium: Trailblazing in Cancer Immunotherapy, October 29â€“31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	2.0	0
77	OC-0602 Pattern of care of radiotherapy practice for EBRT patients in Spain. Radiotherapy and Oncology, 2019, 133, S316-S317.	0.3	0
78	Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma.. Journal of Clinical Oncology, 2014, 32, TPS3129-TPS3129.	0.8	0
79	Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3113-TPS3113.	0.8	0
80	Abstract 4058: Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. , 2015, , .		0
81	Abstract 4015: Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands. , 2016, , .		0
82	Abstract 4012: Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy. , 2016, , .		0
83	Abstract LB-151: Prophylactic TNFÎ± blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations. , 2018, , .		0